PVM
XERS icon

Palogic Value Management’s Xeris Biopharma Holdings XERS Stock Holding History

Palogic Value Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Buy
50,068
+68
+0.1% +$434 0.13% 150
2026
Q1 		$290K Buy
+50,000
New +$332K 0.12% 147

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Palogic Value Management's XERS Position: Q2 2026 in Review

Palogic Value Management increased its Xeris Biopharma Holdings (XERS) stake by 0.14% in Q2 2026, buying an estimated $434 and bringing the position to 50,068 shares worth $397K. The position accounts for 0.13% of the portfolio, ranked #150.

Palogic Value Management first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Palogic Value Management held 50,068 shares of Xeris Biopharma Holdings worth $397K as of Q2 2026.
  • Palogic Value Management bought 68 Xeris Biopharma Holdings shares in Q2 2026, an estimated $434.
  • Xeris Biopharma Holdings made up 0.13% of Palogic Value Management's portfolio in Q2 2026, its #150 holding.
  • Palogic Value Management first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Palogic Value Management's 13F filing for Q2 2026, filed 14 Aug 2026.